Dr. Ellis on Hopeful ER+/HER2- Breast Cancer Paradigms

Matthew J. Ellis, MD, PhD
Published: Wednesday, Sep 14, 2011

Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, explains that he anticipates a paradigm between other rare forms of cancer and estrogen receptor (ER) positive/HER2-negative breast cancer.

Ellis hopes to find something similar to the use of imatinib for Ph+ CML. In this case a fusion gene, BCR-ABL, activates the tumor cells, by inhibiting the mutation you can get rid of the tumor. In breast cancer an example would be Herceptin and other agents for HER2 amplifications.

Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, explains that he anticipates a paradigm between other rare forms of cancer and estrogen receptor (ER) positive/HER2-negative breast cancer.

Ellis hopes to find something similar to the use of imatinib for Ph+ CML. In this case a fusion gene, BCR-ABL, activates the tumor cells, by inhibiting the mutation you can get rid of the tumor. In breast cancer an example would be Herceptin and other agents for HER2 amplifications.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x